Announcements
- Addex Shareholders Approve All Resolutions at Annual General Meeting
- Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
- Addex Convenes Annual General Meeting 2024
- Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
- Addex to Present at Bio€quity Europe 2024
- Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
- Addex to Present at the Swiss Biotech Day 2024
- Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
- Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
- Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
More ▼
Key statistics
On Friday, Addex Therapeutics Ltd (ADXN:NAQ) closed at 8.67, 73.40% above the 52 week low of 5.00 set on Dec 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.15 |
---|---|
High | 8.67 |
Low | 8.15 |
Bid | 7.88 |
Offer | 9.90 |
Previous close | 7.84 |
Average volume | 1.51k |
---|---|
Shares outstanding | 1.54m |
Free float | 1.48m |
P/E (TTM) | -- |
Market cap | 13.31m USD |
EPS (TTM) | -14.87 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 20:24 BST.
More ▼